Equities research analysts expect Zogenix (NASDAQ:ZGNX) to report ($0.90) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Zogenix’s earnings. The highest EPS estimate is ($0.88) and the lowest is ($0.93). Zogenix also posted earnings of ($0.90) per share during the same quarter last year. The firm is scheduled to issue its next earnings results on Tuesday, August 14th.

On average, analysts expect that Zogenix will report full year earnings of ($3.89) per share for the current year, with EPS estimates ranging from ($4.61) to ($3.37). For the next financial year, analysts anticipate that the business will report earnings of ($2.35) per share, with EPS estimates ranging from ($3.69) to ($1.41). Zacks Investment Research’s EPS averages are a mean average based on a survey of research analysts that that provide coverage for Zogenix.

Zogenix (NASDAQ:ZGNX) last posted its quarterly earnings results on Wednesday, May 9th. The company reported ($0.87) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.74) by ($0.13). During the same period last year, the company posted ($0.86) earnings per share.

Several research firms have recently issued reports on ZGNX. Mizuho restated a “buy” rating and issued a $51.00 price target on shares of Zogenix in a research report on Thursday, May 10th. ValuEngine upgraded Zogenix from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, May 2nd. Zacks Investment Research upgraded Zogenix from a “hold” rating to a “buy” rating and set a $50.00 price target on the stock in a research report on Thursday, March 15th. BidaskClub upgraded Zogenix from a “hold” rating to a “buy” rating in a research report on Saturday, February 10th. Finally, Leerink Swann restated an “outperform” rating on shares of Zogenix in a research report on Sunday, March 4th. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $53.20.

Zogenix opened at $42.00 on Thursday, Marketbeat reports. Zogenix has a 12-month low of $10.05 and a 12-month high of $45.85.

In other Zogenix news, Director Roger Hawley sold 35,000 shares of Zogenix stock in a transaction dated Tuesday, March 13th. The stock was sold at an average price of $44.71, for a total transaction of $1,564,850.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders own 5.00% of the company’s stock.

Hedge funds have recently bought and sold shares of the business. SG Americas Securities LLC bought a new position in Zogenix during the first quarter worth about $100,000. Meadow Creek Investment Management LLC bought a new position in Zogenix during the first quarter worth about $192,000. Neuburgh Advisers LLC bought a new position in Zogenix during the first quarter worth about $264,000. Tyers Asset Management LLC bought a new position in Zogenix during the first quarter worth about $337,000. Finally, WINTON GROUP Ltd bought a new position in Zogenix during the first quarter worth about $376,000. Hedge funds and other institutional investors own 99.36% of the company’s stock.

Zogenix Company Profile

Zogenix, Inc, a pharmaceutical company, develops and commercializes therapies for the treatment of central nervous system disorders in the United States. Its lead product candidate is the ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome.

Get a free copy of the Zacks research report on Zogenix (ZGNX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Zogenix (NASDAQ:ZGNX)

Receive News & Ratings for Zogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix and related companies with MarketBeat.com's FREE daily email newsletter.